Pharming Group (PHGUF) Expected to Post Earnings on Tuesday

Pharming Group (OTCMKTS:PHGUF) is expected to release its results before the market opens on Tuesday, October 27th. Analysts expect the company to announce earnings of $0.0150 per share and revenue of $117.60 million for the quarter.

Pharming Group Stock Performance

OTCMKTS:PHGUF opened at $0.95 on Friday. The stock has a market cap of $640.54 million, a price-to-earnings ratio of 79.54 and a beta of 0.42. Pharming Group has a one year low of $0.93 and a one year high of $2.17. The company has a debt-to-equity ratio of 0.39, a quick ratio of 2.31 and a current ratio of 3.01. The business’s 50-day simple moving average is $1.07 and its 200 day simple moving average is $1.25.

Pharming Group Company Profile

Pharming Group N.V. is a commercial-stage biopharmaceutical company headquartered in Leiden, the Netherlands. The company develops and commercializes medicines for rare diseases and conditions with limited treatment options, with a focus on therapies that address unmet medical needs.

Pharming’s principal product is Ruconest, a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause potentially severe swelling. The company also markets Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome, a rare primary immunodeficiency and immune dysregulation disorder.

Founded in 1988, Pharming has developed a commercial presence in the United States and Europe and works with regional partners and distributors in selected international markets.